All Articles in: Boston Scientific
Boston Scientific will be hoping its new S-ICD will prove popular based on its advantages over conventionally placed leads
First-Of-Its-Kind alternative to long-term Warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation
Launch and First Implant of Boston Scientific’s Long-Lasting ICDFebruary 3, 2015
The new Extended Longevity ICDs, featuring EnduraLife battery technology promise almost twelve years
Whatever the value of retrospective data, Boston Scientific is touting results that make a solid case for its Precision Spectra spinal cord stimulator system
Boston Scientific SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance EndpointsNovember 20, 2014
Boston Scientific reports that its SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in the first successful U.S. pivotal trial of a bioabsorbable polymer stent.
CE Mark for Boston’s Pacemaker Opens MRI Conditionality OptionsOctober 17, 2014
When implanted with Boston Scientific’s INGEVITY™ leads, Boston Scientific’s ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems.
Expert Panel review has culminateded in a vote in favour of Boston Scientific Corporation’s WATCHMAN™ Left Atrial Appendage Closure Device.
Tangled Web Sees ICD Inventor Awarded $309 Million for nowSeptember 26, 2014
The family of the man who helped invent the ICD has been awarded $309 million against Boston Scientific, although appeals loom.
It’s good news/bad news for Boston Scientific’s Vagus Nerve Stimulation plans as a heart failure therapy. While efficacy endpoints suggested no outcome improvement, patients in the treatment group of the sham controlled study reported quality of life improvement.
Sounds like a plan. Combine the offerings of one of the Cardiovascular big boys with wire forming company’s expertise and FFR technology is likely to benefit.
Boston Scientific’s Agent™ Paclitaxel-Coated PTCA Balloon Catheter has gained CE mark approval and will now be launched in Europe.
U.S. FDA approval of REBEL™ Platinum Chromium Coronary Stent brings the benefits of modern stent architecture to patients not suitable for drug eluting variants.
Boston Scientific’s Lotus™ TAVI System has been enhanced by the addition of a 25mm variant to its CE marked portfolio.
Boston Scientific Corporation has received CE Mark for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter which is now to be fully launched in Europe.
One year data demonstrate highly significant improvement in motor function for patients with Parkinson’s Disease when treated with Boston Scientific’s Vercise DBS system
New data presented at EuroPCR 2014 in Paris suggests impressive performance at six months for the Lotus™ Valve System, with 79.8 percent of patients showing no paravalvular aortic regurgitation at six months with no cases of severe paravalvular aortic regurgitation in any patient.
<< Previous Articles